ONCE-DAILY INSULIN GLARGINE COMPARED WITH TWICE-DAILY NPH INSULIN IN PATIENTS WITH TYPE 1 DIABETES

2004 ◽  
Vol 10 (1) ◽  
pp. 10-17 ◽  
Author(s):  
Kenneth S. Hershon ◽  
Thomas C. Blevins ◽  
Thomas C. Blevins ◽  
Thomas C. Blevins
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Nph Insulin ◽  
Once Daily ◽  
Daily Insulin

1105-P: Impact of Switching from Twice-Daily Basal Insulin (BI) to Once-Daily Insulin Glargine 300 U/mL (Gla-300) in Patients with Type 1 Diabetes (T1DM): Phase 4 Optimize Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1105-P
Author(s):  
CHANTAL MATHIEU ◽  
PETER STELLA ◽  
JACQUES BRUHWYLER ◽  
KATHY C. ALEXANDRE
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Once Daily ◽  
Daily Insulin

scholarly journals Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy

2007 ◽  
Vol 64 (4) ◽  
pp. 247-252 ◽  
Author(s):  
Milica Pesic ◽  
Sasa Zivic ◽  
Sasa Radenkovic ◽  
Milena Velojic ◽  
Dragan Dimic ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Insulin Aspart ◽  
Basal Insulin ◽  
Nph Insulin ◽  
Once Daily ◽  
Meal Time

Background/Aim. Insulin glargine is a long-acting insulin analog that mimics normal basal insulin secretion without pronounced peaks. The aim of this study was to compare insulin glargine with isophane insulin (NPH insulin) for basal insulin supply in patients with type 1 diabetes. Methods. A total of 48 type 1 diabetics on long term conventional intensive insulin therapy (IIT) were randomized to three different regimens of basal insulin substitution: 1. continuation of NPH insulin once daily at bedtime with more intensive selfmonitoring (n = 15); 2. NPH insulin twice daily (n = 15); 3. insulin glargine once daily (n = 18). Meal time insulin aspart was continued in all groups. Results. Fasting blood glucose (FBG) was lower in the glargine group (7.30?0.98 mmol/l) than in the twice daily NPH group (7.47?1.06 mmol/l), but without significant difference. FBG was significantly higher in the once daily NPH group (8.44?0.85 mmol/l; p < 0.05). HbA1c after 3 months did not change in the once daily NPH group, but decreased in the glargine group (from 7.72?0.86% to 6.87?0.50%), as well as in the twice daily NPH group (from 7.80?0.83% to 7.01?0.63%). Total daily insulin doses were similar in all groups but only in the glargine group there was an increase of basal and decrease of meal related insulin doses. The frequency of mild hypoglycemia was significantly lower in the glargine group (6.56?2.09) than in both NPH groups (9.0?1.65 in twice daily NPH group and 8.13?1.30 in other NPH group) (episodes/patients-month, p < 0.05). Conclusion. Basal insulin supplementation in type 1 diabetes mellitus with either twice daily NPH insulin or glargine can result in similar glycemic control when combined with meal time insulin aspart. However, with glargine regimen FBG, HbA1c and frequency of hypoglycemic event are lower. These facts contribute to better patients satisfaction with insulin glargine versus NPH insulin in IIT in type 1 diabetics.

Sign in / Sign up

Export Citation Format

Share Document